RxDoctor Payments Data

Adam Bloom, MD

Ophthalmology · Huntington, NYNPI 1740375047

Payments from drug & device makers

$2,587in general payments, 2019–2025

Across 133 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$635
  • Alcon$453
  • Sun Pharmaceutical Industries Inc.$213
  • Kala Pharmaceuticals, Inc.$160
  • Biotissue Holdings Inc.$140
  • Oyster Point Pharma, Inc.$103
  • plus $884 from 16 others

What the payments were for

  • Food & beverage$2,56999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,587 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$753,496
Medicare patients
2,156
Services billed
7,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$132,256
LumiganBimatoprost75$41,007
RocklatanNetarsudil Mesylat/Latanoprost59$33,719
ProlensaBromfenac Sodium90$29,790
XiidraLifitegrast16$28,067
IlevroNepafenac34$12,343
RhopressaNetarsudil Mesylate20$11,937
Prednisolone Acetate429$11,697
Latanoprost689$7,968
CombiganBrimonidine Tartrate/Timolol20$7,745
Cyclosporine13$7,563
Fluorometholone101$6,268
SimbrinzaBrinzolamide/Brimonidine Tart20$4,223
Ofloxacin294$2,897
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat174$2,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$635$181,009176 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$33$45,65579 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$89$29,79090 claims
Bausch & Lomb Americas Inc.Xiidra$84$28,06716 claims
NovartisIlevro$63$12,34334 claims
AlconSimbrinza$453$4,22320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →